Document is current
Any future updates will be listed below
-
Authors
Nakajima, Kenichi https://orcid.org/0000-0001-7188-8746
Doi, Takahiro
Nakata, Tomoaki
Nakahashi, Takuya
Tada, Hayato
Wakabayashi, Hiroshi
Verberne, Hein J.
-
Funding
Funding for this research was provided by:
Kanazawa University
- License Information
-
More Information
Article History
Received: 30 October 2025
Accepted: 12 January 2026
First Online: 29 January 2026
Declarations
:
: All methods were applied according to the ethical standards enshrined in the Declaration of Helsinki (2013 amendment) or comparable ethical standards. The Ethics Committee at Kanazawa University approved this retrospective study (Approval number: 1553/3020) and waived the need for written, informed consent to participate because only anonymized and retrospective data were analyzed. Participation in this multicenter study was approved by the ethics committees at each institution or followed comparable guidelines.
: K. Nakajima was affiliated with a department endowed by PDRadiopharma (Tokyo, Japan), Nihon Medi-Physics (Tokyo, Japan), and Siemens Healthcare Japan (Tokyo, Japan) till 2024, and has a collaborative research agreement with PDRadiopharma, Inc. (Tokyo, Japan), which markets 123 I- m IBG (myoMIBG™) in Japan. The company had no role in data collection, analysis, interpretation, or manuscript preparation.
